. (“Allied”) (
OTCQB: ALID) – an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce that it has signed a letter of intent (LOI) with Fiore Cannabis Ltd. (CSE: FIORE) (“Fiore”) to acquire a US registered cultivation license located within in the State of Nevada, USA. In addition to this, the LOI contemplates a land lease agreement for the land foot print upon which the ready built Allied 9000 square foot building will be installed.
Allied has completed the construction of a $3.5 million, 9000 square foot, GMP-complaint facility that is ready to be deployed from the Las Vegas construction factory. The building has ample space for cannabis cultivation and research, as well as, large scale product packaging and fulfillment. In addition to this, Allied has reserved a space within this building to conduct Psilocybin research and production as the legislation allows. This build
Allied Corp. (OTCQB:ALID) is purchasing a registered cultivation license in Nevada.
The deal includes a GMP-complaint facility worth $3.5 million and a land lease for the installment of Allied 9000 square foot building.
On the sell side is
Fiore Cannabis Ltd., which agreed to utilize its medical and retail channels to support the marketing and sale of products manufactured at the new facility.
The company, which has been constructing the building for 18 months, also has a space designed specifically for psilocybin production and research.
In December, Kelowna, British Columbia-based Allied announced a purchase agreement for psilocybin company Pacific Sun Fungi.
Allied also operates a Colombia-based farm through its subsidiary, MediColombias Cannabis S.A.S., a licensed producer of cannabis for medical, research, and industrial applications.
Allied Corp. (OTC:ALID) is taking the next step on its road to joining the psilocybin space.
The British Columbia-based company said it signed a letter of intent to buy the psilocybin company
Pacific Sun Fungi.
This move comes as the next logical step in the company’s growth plans, as Allied previously announced it has submitted a provisional patent application for the company’s mushroom formulation focusing on depression and anxiety disorders.
Pacific Sun is known for its
psilocybin-focused research and development activities over the last 10 years, formulating several proprietary technologies and formulations.
Allied Corp. said it was initially created with the goal to develop and secure cannabinoid therapies for veterans and others who suffer from post-traumatic stress disorder.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Allied Moves to Become Leader in Psilocybin Space with Intent to Acquire of Pacific Sun Fungi
Allied Corp.December 24, 2020 GMT
KELOWNA, British Columbia, Dec. 24, 2020 (GLOBE NEWSWIRE) Allied Corp. (“Allied”) (OTCQB: ALID) – an international medical cannabis company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce the signing of a letter of intent to acquire the psilocybin company Pacific Sun Fungi (“Pacific Sun”). This further expands upon Allied’s press release of October 20, 2020 communicating the submission of the provisional patent for Allied’s functional mushroom formulation targeting major depression and anxiety.
. ( Allied ) (
OTCQB: ALID) – an international medical cannabis company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce the signing of a letter of intent to acquire the
psilocybin company Pacific Sun Fungi (“
Pacific Sun”). This further expands upon Allied’s press release of October 20, 2020 communicating the submission of the provisional patent for Allied’s functional mushroom formulation targeting major depression and anxiety.
Pacific Sun is a British Columbia corporation that has been working on Research and Development activities in the psilocybin space for the past 10 years. Pacific Sun holds several formulations that have been tested under physician supervision. Pacific Sun also has proprietary extraction technology, proprietary formulations for several specific disease targets and physician-led therapy protocols that have proven to be effective for several specific disease targets.